Rheumatology Medical News about Jevenile RA;Infliximab plus Methotrexate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an open-label treatment extension
Annals of Rheumatic Diseases, 05/08/09

Ruperto N et al. – In the limited population of juvenile rheumatoid arthritis (JRA) patients remaining in the study through 4 years, infliximab was safe and effective but associated with a high patient discontinuation rate.

Methods

Study to assess long-term efficacy and safety of infliximab plus methotrexate (MTX) in JRA
Pts eligible for the open-label extension (OLE, weeks 52-204) received infliximab 3-6 mg/kg q8wks plus MTX

Results

Of the 78/122 (64%) children entering the OLE, 42 discontinued infliximab, most commonly due to:
- consent withdrawal (11 pts)
- lack of efficacy (8 pts) or
- patient/physician/sponsor requirement (8 pts)
Infliximab (mean dose=4.4 mg/kg/infusion) was generally well tolerated
Infusion reactions occurred in 32% (25/78) of pts, with a higher incidence in pts positive for Abs to infliximab (58%, 15/26)
At wk 204, the proportions of pts achieving ACR-Pedi-30/50/70/90 response criteria and inactive disease status were 44%, 40%, 33%, 24%, and 13%, respectively

<< Previous
Assessment of active spinal inflammatory changes in patients with...

Next >>
STIM1 mutation associated with a syndrome of immunodeficiency and...